CharlesJLinkJr.MDFACP

Oncology • Fort Lauderdale, FL

Executive Chairman Syncromune, Inc

Join to view full profile

Dr. Link is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Link's full profile

Already have an account?

Office
2919 Commercial Blvd
Fort Lauderdale, FL 33308
Phone+1 954-769-1036

Summary

immuno-oncology

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1988 - 1992
University of California (San Francisco)Residency, Internal Medicine, 1985 - 1988
Stanford University School of MedicineClass of 1985

Certifications & Licensure

IA State Medical License 1993 - 2025
CA State Medical License 1987 - 1990
American Board of Internal Medicine Internal Medicine

Clinical Trials

Vaccine Study for Surgically Resected Pancreatic Cancer Start of enrollment: 2007 Dec 01
Completed
Phase 2
Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer Start of enrollment: 2008 Jan 01
Terminated
Phase 2
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors Start of enrollment: 2008 Aug 01
Terminated
Phase 1
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer Start of enrollment: 2012 Oct 01
Completed
Phase 2
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma Start of enrollment: 2014 Jul 01
Completed
Phase 1, Phase 2
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Start of enrollment: 2014 Aug 01
Completed
Phase 1, Phase 2
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors Start of enrollment: 2015 Oct 01
Completed
Phase 1
A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2016 Jul 01
Completed
Phase 1
A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma Start of enrollment: 2017 Dec 08
Terminated
Phase 2
Oral Bioavailability,and Food Effect Study and Single Ascending Dose PK Study in Healthy Male Volunteers Start of enrollment: 2017 Nov 21
Completed
Phase 1
Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers Start of enrollment: 2018 Mar 05
Completed
Early Phase 1
Join now to see all

Publications & Presentations

PubMed

56 citations
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.
Yousef Zakharia, Robert R. McWilliams, Olivier Rixe, Joseph J. Drabick, Montaser Shaheen
Journal for Immunotherapy of Cancer. 2021-06-11
32 citations
Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial.
Veronica Mariotti, Hyo S. Han, Roohi Ismail-Khan, Shou-Ching Tang, Patrick M. Dillon
JAMA Oncology. 2021-01-01
44 citations
A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects with Borderline Resectable or Local...
D Brock Hewitt, Nicholas Nissen, Hassan Hatoum, Benjamin L. Musher, John Seng
Annals of Surgery. 2020-12-22

Professional Memberships

American Society of Clinical Oncology - ASCO
Member